CHIUN HSUSHU-CHEN WEIANN-LII CHENGPEI-JER CHEN2021-06-152021-06-1520090270-9139https://www.scopus.com/inward/record.uri?eid=2-s2.0-68949172200&doi=10.1002%2fhep.23067&partnerID=40&md5=98db72b0d52f92e5f622d3201243a528https://scholars.lib.ntu.edu.tw/handle/123456789/565716[SDGs]SDG3entecavir; hepatitis B surface antigen; immunosuppressive agent; lamivudine; rituximab; tenofovir; antiviral therapy; hepatitis B; Hepatitis B virus; high risk patient; human; immune system; immunocompetence; immunosuppressive treatment; letter; lymphoma; priority journal; remission; side effect; toxic hepatitis; treatment duration; virus mutation; virus reactivation; chemically induced disorder; hepatitis B; recurrent disease; Hepatitis B; Humans; Immunosuppressive Agents; Recurrenceletter10.1002/hep.23067196421672-s2.0-68949172200